FAM13A: A Drug Target / Disease Biomarker (G10144)

Target Name: FAM13A

NCBI ID: G10144

FAM13A

FAM13A: A Drug Target / Disease Biomarker

FAM13A is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its function and potential uses are being studied in a number of research contexts, and its potential as a drug target are being investigated in both human and animal models.

The FAM13A gene is located on chromosome 13q31 and encodes a protein known as FAM13A, which is a member of the superfamily of the FAM13A gene family. This family of proteins is characterized by the presence of a unique domain called the FAM13A signature, which is a conserved motif that is found in a number of proteins that are involved in a variety of cellular processes, including cell signaling, DNA replication, and stress response.

One of the unique features of FAM13A is its ability to interact with a variety of different proteins, including tyrosine kinases, which are a type of protein that can modulate the activity of other proteins by binding to their tyrosine residues. This interaction between FAM13A and tyrosine kinases makes it a potentially interesting drug target, as drugs that can modulate tyrosine kinase activity have been shown to be effective in treating a variety of diseases, including cancer and neurodegenerative disorders.

In addition to its potential as a drug target, FAM13A is also being investigated as a biomarker for a number of diseases. For example, studies have shown that FAM13A is expressed in a variety of human tissues and that its levels can be affected by a variety of factors, including cancer treatment, stress, and neurodegenerative disorders. As a result, FAM13A has been suggested as a potential biomarker for a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Another potential use for FAM13A as a drug target is its role in the regulation of cellular processes that are involved in the development and progression of cancer. For example, studies have shown that FAM13A is involved in the regulation of cell proliferation, and that it can interact with proteins that are involved in cell signaling pathways that promote cancer growth. As a result, FAM13A has been suggested as a potential target for drugs that can inhibit its activity, potentially by inhibiting the growth and survival of cancer cells.

In addition to its potential as a drug target and biomarker, FAM13A is also being investigated for its potential role in treating neurodegenerative disorders. For example, studies have shown that FAM13A is involved in the regulation of cellular processes that are involved in the development and progression of neurodegenerative disorders, and that it can interact with proteins that are involved in the regulation of neuronal excitability. As a result, FAM13A has been suggested as a potential target for drugs that can modulate its activity, potentially by treating neurodegenerative disorders.

Overall, FAM13A is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Its unique ability to interact with a variety of different proteins, including tyrosine kinases, makes it a potentially interesting target for drugs that can modulate its activity. Additionally, its potential as a biomarker for a variety of diseases, including cancer and neurodegenerative disorders, makes it an important area of research for the development of new treatments.

Protein Name: Family With Sequence Similarity 13 Member A

The "FAM13A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM13A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets